OBESITY

GLOBAL CLINICAL TRIAL LANDSCAPE (2025)

#DYK
Did you
know?



Obesity is a **chronic**

disease

characterized

bv

excessive

fat

accumu-

lation

that

poses

signifi-

cant

health

risks



The **United States** is one of the leading countries in the Americas for adult overweight and obesity prevalence

The **UK leads major European countries** in adult overweight and obesity prevalence, followed by Russia and Germany

The **Western Pacific region** is witnessing a rising prevalence of obesity, with Australia and New Zealand among the most impacted

Southeast Asia shows lower obesity prevalence, with rising rates in Thailand, China, and India, followed by ROW



GLP-1-based
therapies, led
by drugs like
Wegovy and
Rybelsus, dominate the obesity
drug pipeline



ple agonists like retatrutide and cagrisema reflect a shift toward multi-target obesity treatments

Emerging dual/tri-

OBESITY TRIAL CONTRIBUTIONS

Countries like the United States, Mainland China, South Korea, Germany, and Australia, emerged as top locations for conducting trials.

